Please use this identifier to cite or link to this item:
|Title:||Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection|
|Citation:||Reynard, O., Mokhonov, V., Mokhonova, E., Leung, J., Page, A., Mateo, M., Pyankova, O., Georges-Courbot, M.C., Raoul, H., Khromykh, A.A., Volchkov, V.E. (2011-11-01). Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. Journal of Infectious Diseases 204 (SUPPL. 3) : S1060-S1065. ScholarBank@NUS Repository. https://doi.org/10.1093/infdis/jir347|
|Abstract:||Pre- or postexposure treatments against the filoviral hemorrhagic fevers are currently not available for human use. We evaluated, in a guinea pig model, the immunogenic potential of Kunjin virus (KUN)-derived replicons as a vaccine candidate against Ebola virus (EBOV). Virus like particles (VLPs) containing KUN replicons expressing EBOV wild-type glycoprotein GP, membrane anchor-truncated GP (GP/Ctr), and mutated GP (D637L) with enhanced shedding capacity were generated and assayed for their protective efficacy. Immunization with KUN VLPs expressing full-length wild-type and D637L-mutated GPs but not membrane anchor-truncated GP induced dose-dependent protection against a challenge of a lethal dose of recombinant guinea pig-adapted EBOV. The surviving animals showed complete clearance of the virus. Our results demonstrate the potential for KUN replicon vectors as vaccine candidates against EBOV infection. © 2011 The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.|
|Source Title:||Journal of Infectious Diseases|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 22, 2019
WEB OF SCIENCETM
checked on Jan 14, 2019
checked on Jan 11, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.